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Introduction {#sec008}
============

Observational studies have suggested a benefit of certain blood pressure medications on reducing the risk of developing dementia \[[@pmed.1002660.ref001]\]. Particular antihypertensive agents have also been shown to decrease Alzheimer disease pathology in the brains of people with hypertension, independently of blood pressure control, suggesting a direct effect of these medications against the biological processes underpinning Alzheimer disease \[[@pmed.1002660.ref002],[@pmed.1002660.ref003]\]. One antihypertensive, for which there is clinical and scientific rationale for disease-modifying efficacy in Alzheimer disease, is nilvadipine. Nilvadipine is a dihydropyridine (DHP) calcium channel blocker and is licensed in a number of countries to treat patients with hypertension. Nilvadipine is reported to have a number of neuroprotective mechanisms of action other than direct calcium channel blockade and maintenance of intracellular calcium homeostasis, including lowering Amyloid beta 40 and 42 amino acid peptides (Aβ40 and Aβ42) production in vitro and in vivo in transgenic mouse models of Alzheimer disease, and enhancing Aβ clearance across the blood--brain barrier in in vivo mouse models \[[@pmed.1002660.ref004],[@pmed.1002660.ref005]\]. However, many other DHPs do not share these properties and some may actually increase Aβ40 and Aβ42 production in vitro \[[@pmed.1002660.ref004]\], demonstrating that amyloid lowering is not a class effect of DHPs. In addition to effects on Aβ production and clearance, nilvadipine specifically has also shown efficacy against a broad range of other putative Alzheimer disease pathological mechanisms, including tau-phosphorylation, reduced cerebral blood flow, and neuroinflammation \[[@pmed.1002660.ref006]--[@pmed.1002660.ref009]\].

In clinical studies, nilvadipine stabilised cognitive decline and reduced conversion to Alzheimer disease in a small study of patients with hypertension and mild cognitive impairment \[[@pmed.1002660.ref010]\]. Another 6-week open label study demonstrated that nilvadipine was safe and well tolerated in patients with Alzheimer disease and did not reduce blood pressure in nonhypertensive patients with Alzheimer disease, but appropriately lowered blood pressure in hypertensive cases \[[@pmed.1002660.ref011]\].

These studies are complemented by a number of epidemiological and interventional studies involving different calcium channel blockers that have reported on the potential benefit of this drug class in the prevention of Alzheimer disease. In the treatment of Systolic Hypertension in Europe (Syst-Eur) trial, which involved over 2,400 older participants with systolic hypertension treated with the DHP calcium channel blocker, nitrendipine, there was a reported 55% reduction in the incidence of Alzheimer disease \[[@pmed.1002660.ref012],[@pmed.1002660.ref013]\]. The Baltimore Longitudinal Study of Aging found a nonsignificant apparent benefit towards reduced relative risk of Alzheimer disease in patients treated with DHP calcium channel blockers, with no lowered risk observed in the non-DHP calcium channel blocker treatment group \[[@pmed.1002660.ref014]\].

To our knowledge, there has been no definitive intervention study with a calcium channel blocker to test for an effect on slowing the rate of cognitive decline in patients with Alzheimer disease.

Given the previous preclinical and clinical data suggesting the potential efficacy for nilvadipine and related compounds against Alzheimer disease, the objective of this 78-week randomised, placebo-controlled study was to determine whether treatment with nilvadipine sustained-release 8 mg, once a day, was effective and safe in slowing the rate of cognitive decline in patients with mild to moderate Alzheimer disease.

Methods {#sec009}
=======

Study design {#sec010}
------------

This 18-month Phase III, randomised, placebo-controlled, double-blind, parallel-group study was carried out at 23 academic centres in nine European countries: Ireland (two sites), United Kingdom (one site), Italy (four sites), the Netherlands (three sites), France (seven sites), Greece (three sites), Sweden (one site), Germany (one site), and Hungary (one site) ([S1 Table](#pmed.1002660.s005){ref-type="supplementary-material"}). The trial project office was based at St. James's Hospital, Dublin, Ireland, which was also the sponsor. The trial coordinating institution was Trinity College, University of Dublin, and the trial was funded by the European Commission, under a Framework 7 Programme Health Theme collaborative project grant. The trial database, randomisation, and allocation system were maintained by the Clinical Trials Unit at King's College London, and the statistical analysis was conducted at the University College Dublin Centre for Support and Training in Analysis and Research (UCD CSTAR). As part of the overall governance of the trial, there was a Scientific Advisory Board, an independent Ethics Advisory Board, and an independent Data Safety Monitoring Board. Approval of the study protocol and all related documents was obtained from the appropriate National Competent Authorities, Independent Ethics Committees, and Institutional Review Boards for all study sites. Additional information is provided below and in supplementary files [S1 Text](#pmed.1002660.s001){ref-type="supplementary-material"} (study design and treatment), [S2 Text](#pmed.1002660.s002){ref-type="supplementary-material"} (detailed statistical methods), and [S3 Text](#pmed.1002660.s003){ref-type="supplementary-material"} (trial-associated boards).

Participants {#sec011}
------------

A detailed list of inclusion and exclusion criteria is provided in the published protocol \[[@pmed.1002660.ref015]\]. Briefly, participants were aged \>50 years, meeting National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's disease Criteria (NINCDS-ADRDA) for diagnosis of probable Alzheimer disease \[[@pmed.1002660.ref016]\], with a Standardised Mini-Mental State Examination (SMMSE) \[[@pmed.1002660.ref017]\] score of ≥12 and \<27, and having a caregiver available to complete relevant assessment instruments. If on a cholinesterase inhibitor or memantine, the dose had to be stable for \>12 weeks. People with dementia because of other causes or with known sensitivity to calcium channel blockers were excluded.

All participants provided written informed consent before enrolling in the study. The consent form was amended as required in each country to comply with local ethics requirements. All caregivers also provided consent for involvement.

Randomisation and masking {#sec012}
-------------------------

Participants were randomly assigned to nilvadipine sustained-release 8 mg or placebo using block randomisation with randomly varying block sizes, stratified by site, using an online system integrated with stock control across sites. Participants, caregivers, and assessors were blinded to treatment assignment.

Procedures {#sec013}
----------

Participants took a trial treatment capsule once a day after breakfast for 78 weeks and returned their used treatment boxes at subsequent dispensing visits, when the number of returned capsules was recorded. Participants were assessed at 6, 13, 26, 39, 52, 65, and 78 weeks after commencing treatment. Participants were followed up 4 weeks after the final, week 78 visit.

Outcomes {#sec014}
--------

The co-primary outcome measures were the change from baseline in the 12-item Alzheimer Disease Assessment Scale--Cognitive Subscale (ADAS-Cog 12) \[[@pmed.1002660.ref018]\] and the Clinical Dementia Rating scale sum of boxes (CDR-sb) \[[@pmed.1002660.ref019]\]. The key secondary outcome measure was the Disability Assessment for Dementia (DAD) \[[@pmed.1002660.ref020]\], as maintenance of functional abilities is considered a crucial benefit of any potential treatment. Data on all primary and secondary outcome measures were collected at baseline and at 13, 52, and 78 weeks. Safety was assessed through the collection of data on adverse events (AEs), blood pressure, and laboratory tests.

Statistical analysis {#sec015}
--------------------

The sample size of 250 patients in each group was calculated to allow detection of a 50% reduction in cognitive decline in the nilvadipine group over the 78 weeks of follow-up \[[@pmed.1002660.ref015]\]. This resulted in 90% power to detect a 3.5-point group difference in the decline in ADAS-Cog 12 (SD = 10), and 81% power to also detect a significant effect on the CDR-sb as a gated co-primary end point. The sample size calculation included allowance for 30% loss to follow-up.

The primary and secondary efficacy analyses were conducted in a modified intention-to-treat (mITT) population, including all participants randomised who had both a baseline assessment and at least one later assessment. The safety set included all patients who took at least one dose of the trial treatment.

A secondary per-protocol analysis was carried out using only those patients compliant with medication (defined as taking \>80% of doses) and with all assessments on schedule.

The primary and secondary end point analyses consisted of linear mixed-effects models, with country as a random effect and correlated residuals over time. Findings hinged on a *p*-value less than 0.05 for a (Visit × Arm) interaction test using change scores from baseline and adjusting for the baseline score. We adopted a gated approach to control the false positive rate over multiple end points. The ordered outcomes were as follows: change from baseline of ADAS-Cog 12 (analysed in discrete time); followed by the change in CDR-sb; then, in order, ADAS-Cog 12 and CDR-sb were to be tested for a linear improvement over continuous time. The key secondary outcome of DAD was next on the list, followed by the other secondary outcomes. In the case of a nonsignificant result, any further analyses are purely exploratory, with no further tests of a null hypothesis. Full technical details and description of the gated approach and statistical models are given in the [S1 Text](#pmed.1002660.s001){ref-type="supplementary-material"} file.

Responder analyses were conducted on a dichotomised change score from baseline to week 78 using logistic regression, with no imputation for missing values. Preplanned subgroup analyses included examination of a difference in nilvadipine effect size between mild and moderate Alzheimer disease (≥20 versus \<20 on baseline SMMSE, respectively), between males and females, and between Apolipoprotein E gene (*APOE*) ε4 allele carriers and noncarriers. The latter analysis was limited to the patient subgroup that participated in the blood biomarker study \[[@pmed.1002660.ref021]\]. Subgroup differences in efficacy were examined by a three-way interaction of the subgroup with visit and treatment arms.

Baseline and safety end points were tested by standard tests for proportions (Pearson chi-squared test) or rates (Poisson count model), with no corrections applied for multiple testing.

An independent Data Safety Monitoring Board, blind to group assignment, reviewed safety data throughout the trial.

This trial adhered to the Declaration of Helsinki and International Conference on Harmonisation Good Clinical Practice (ICH GCP) guidelines and was conducted in compliance with the protocol, data protection regulations, and all other regulatory requirements, as appropriate.

Results {#sec016}
=======

Participants {#sec017}
------------

Between 15 May 2013 and 13 April 2015, 511 eligible participants were randomised; the last outcomes visit was in November 2016. Of the 511 randomised, 498 had at least one post-baseline ADAS-Cog 12 assessment and comprised the mITT population ([Fig 1](#pmed.1002660.g001){ref-type="fig"}), with 247 on nilvadipine and 251 on placebo. The proportion of ADAS-Cog 12 assessments completed was high, allowing us to exceed our sample size target (see [Fig 1](#pmed.1002660.g001){ref-type="fig"}). Trial medication was interrupted by 103 patients during the course of the study (55 nilvadipine, 48 placebo), of whom 4 resumed medication; mean treatment compliance was 88% (capsules taken over days in study), and 80.4% of patients were compliant with assigned medication at a threshold of 80% of capsules taken, balanced between arms.

![Flowchart of the NILVAD study according to the CONSORT guideline.\
ADAS, Alzheimer's Disease Assessment Scale-Cognitive Subscale 12 item; BP, blood pressure; CDR, Clinical Dementia Rating Scale sum of boxes; DAD, Disability Assessment for Dementia; ECG, electrocardiogram; IMP, investigational medicinal product; NILVAD, Nilvadipine in Alzheimer disease; SMMSE, Standardised Mini-Mental State Examination.](pmed.1002660.g001){#pmed.1002660.g001}

Baseline demographic and Alzheimer disease--specific characteristics were similar between treatment groups ([Table 1](#pmed.1002660.t001){ref-type="table"}, [Table 2](#pmed.1002660.t002){ref-type="table"}). There were no significant differences at baseline or end of trial in the prescribing of Alzheimer disease medications (acetylcholinesterase inhibitors and/or memantine) or non-Alzheimer disease concomitant medications ([Table 1](#pmed.1002660.t001){ref-type="table"}). Vascular risk factors, notably hypertension, hypercholesterolemia, and kidney disease, were also similar, with the exception of diabetes, which was more common in the nilvadipine group ([Table 1](#pmed.1002660.t001){ref-type="table"}). Comorbid medical conditions at baseline were substantially more prevalent in the nilvadipine group than in the placebo group, and predominantly in the endocrine class, which included diabetes ([Table 1](#pmed.1002660.t001){ref-type="table"}). *APOE* genotype was available from 161 participants in the nilvadipine group and 167 in the placebo group.

10.1371/journal.pmed.1002660.t001

###### Characteristics of the modified intention-to-treat sample.

![](pmed.1002660.t001){#pmed.1002660.t001g}

  --------------------------------------------------------------------------------------------------------------------------------------
  Characteristics                                  Nilvadipine\                     Placebo\                         
                                                   (*N* = 247)                      (*N* = 251)                      
  ------------------------------------------------ -------------------------------- -------------------------------- -------------------
  Demographics and anthropometrics                                                                                   

      Sex *N* (%)                                  Female                           161 (65%)                        147 (59%)

      Baseline age (years)                         mean (SD)                        73.1 (8.66)                      72.8 (7.84)

      Ethnicity *N* (%)                            White                            241 (98%)                        244 (97%)

  Asian                                            1 (0.4%)                         2 (0.8%)                         

  Black                                            1 (0.4%)                         4 (1.6%)                         

  Other                                            4 (1.6%)                         1 (0.4%)                         

      Baseline BMI                                 mean (SD)                        25.3 (3.92)                      25.8 (4.45)

      Baseline blood pressure                      mean (SD) SBP/DBP                138 (14) / 77 (9)                137 (14) / 77 (9)

      Week 13 blood pressure                       mean (SD) SBP/DBP                131 (15) / 73 (9)                137 (16) / 76 (9)

      Week 52 blood pressure                       mean (SD) SBP/DBP                131 (15) / 74 (9)                135 (14) / 76 (9)

      Week 78 blood pressure                       mean (SD) SBP/DBP                132 (16) / 74 (10)               135 (16) / 75 (9)

  Baseline vascular risk factors                                                                                     

      Diabetes                                     28 (12%)                         12 (5%)                          

      Kidney disease                               3 (1%)                           5 (2%)                           

      Hypercholesterolemia                         82 (34%)                         83 (33%)                         

      Hypertension                                 82 (34%)                         87 (35%)                         

      Baseline blood pressure (median SBP / DBP)   140 / 77                         138 / 77                         

      Week 78 blood pressure (median SBP / DBP)    130 / 74                         135 / 74                         

  Baseline medical status                                                                                            

      Patients on AD concomitant medications       173 (69%) on 1; 65 (26%) on 2+   170 (66%) on 1; 75 (29%) on 2+   

      Patients on non-AD concomitant medications   221 (88%)                        219 (85%)                        

      Comorbid medical conditions (per patient)    mean (SD)                        2.84 (2.09)                      2.43 (1.87)
  --------------------------------------------------------------------------------------------------------------------------------------

Data are mean (standard deviation), median (IQR: first and third quartiles), *n* (%), or *n*/*N* (%).

Abbreviations: AD, Alzheimer disease; BMI, body mass index; DBP, diastolic blood pressure; IQR, interquartile range; SBP, systolic blood pressure.

10.1371/journal.pmed.1002660.t002

###### Baseline Alzheimer disease characteristics.

![](pmed.1002660.t002){#pmed.1002660.t002g}

  --------------------------------------------------------------------------------------
  Characteristics                     Sample statistics   Nilvadipine\   Placebo\
                                                          (*N* = 247)    (*N* = 251)
  ----------------------------------- ------------------- -------------- ---------------
  Years since diagnosis               mean (SD)           1.73 (1.66)    1.70 (1.78)

  Years since symptom onset           mean (SD)           4.31 (2.56)    4.28 (2.72)

  *APOE* ε4 carrier                   *n/N* (%)           94/161 (58%)   100/167 (60%)

  SMMSE                               mean (SD)           20.3 (3.76)    20.5 (3.89)

  SMMSE \< 20                         *N* (%)             93 (38%)       94 (37%)

  Baseline ADAS-Cog 12                mean (SD)           34.4 (10.5)    34.5 (10.8)

  Baseline CDR-sb (*N* = 249 + 251)   mean (SD)           5.34 (2.76)    5.17 (2.73)

  Baseline DAD (*N* = 249 + 251)      mean (SD)           29.7 (8.0)     30.4 (8.1)
  --------------------------------------------------------------------------------------

Data are mean (standard deviation), *n* (%), or *n*/*N* (%).

Abbreviations: ε4, epsilon 4 allele; ADAS-Cog 12, Alzheimer Disease Assessment Scale--Cognitive Subscale (12 item); *APOE*, Apolipoprotein E gene; CDR-sb, Clinical Dementia Rating sum of boxes; DAD, Disability Assessment for Dementia; SMMSE, Standardised Mini-Mental State Examination.

Efficacy end points {#sec018}
-------------------

No treatment effect was observed at a statistically significant level for the first primary outcome analysis (*p* = 0.465). The nilvadipine difference from placebo, in change from baseline in the ADAS-Cog 12 score, was −0.22 (95% CI, −2.01--1.57) ([Table 3](#pmed.1002660.t003){ref-type="table"}). Similarly, nilvadipine did not show any clinically meaningful effects on CDR-sb and DAD ([Table 3](#pmed.1002660.t003){ref-type="table"}, [Fig 2](#pmed.1002660.g002){ref-type="fig"}).

![Estimated marginal means and 95% confidence intervals of the per-visit change from baseline in cognition and functional performance, as measured by the primary and key secondary outcomes, respectively.\
ADAS/ADAS-Cog 12, Alzheimer\'s Disease Assessment Scale Cognitive-12; CDR/CDR-sb, Clinical Dementia Rating Scale sum of boxes; DAD, Disability Assessment for Dementia.](pmed.1002660.g002){#pmed.1002660.g002}

10.1371/journal.pmed.1002660.t003

###### Efficacy analyses for primary outcomes (ADAS-Cog 12 and CDR-sb), and the key secondary outcome (DAD).

![](pmed.1002660.t003){#pmed.1002660.t003g}

  Outcomes                                            Week 0                          Week 13                Week 52                                   Week 78                 *p*-value[\*](#t003fn002){ref-type="table-fn"}                 
  --------------------------------------------------- ------------------------------- ---------------------- ----------------------------------------- ----------------------- ------------------------------------------------ ------------- --
  ADAS-Cog 12[^Ɨ^](#t003fn003){ref-type="table-fn"}   Nilvadipine                     Mean ± SD              34.4 ± 10.5                               35.2 ± 11.3             39.4 ± 13.1                                      41.9 ± 14.6   
  Δ (95% CI)                                                                          0.88 (0.02--1.74)      5.75 (4.66--6.85)                         9.41 (8.09--10.73)                                                                     
  Placebo                                             Mean ± SD                       34.5 ± 10.8            35.3 ± 11.6                               40.3 ± 13.9             41.9 ± 14.5                                                    
  Δ (95% CI)                                                                          0.79 (−0.07--1.64)     6.41 (5.33--7.49)                         9.63 (8.33--10.93)                                                                     
  Group difference                                                                    0.09 (−0.96--1.15)     −0.65 (−2.10--0.80)                       −0.22 (−2.01--1.57)     0.465                                                          
  CDR-sb[^ǂ^](#t003fn004){ref-type="table-fn"}        Nilvadipine                     Mean ± SD              5.34 ± 2.76                               5.87 ± 2.96             7.29 ± 3.69                                      8.72 ± 4.60   
  Δ (95% CI)                                                                          0.54 (0.35--0.72)      2.02 (1.69--2.34)                         3.49 (3.07--3.90)                                                                      
  Placebo                                             Mean ± SD                       5.17 ± 2.73            5.71 ± 3.17                               7.22 ± 4.02             8.38 ± 4.45                                                    
  Δ (95% CI)                                                                          0.51 (0.33--0.70)      2.19 (1.87--2.50)                         3.52 (3.11--3.94)                                                                      
  Group difference                                                                    0.02 (−0.25--0.29)     −0.17 (−0.62--0.28)                       −0.04 (−0.62--0.55)     N/A                                                            
  DAD[^§^](#t003fn005){ref-type="table-fn"}           Nilvadipine                     Mean ± SD              29.7 ± 8.0                                28.4 ± 8.2              24.3 ± 10.2                                      21.1 ± 11.5   
  Δ (95% CI)                                                                          −1.42 (−1.99--−0.85)   −5.68 (−6.60--−4.77)                      −9.02 (−10.14--−7.91)                                                                  
  Placebo                                             Mean ± SD                       30.4 ± 8.1             29.2 ± 8.6                                25.1 ± 10.4             22.8 ± 11.3                                                    
  Δ (95% CI)                                                                          −1.10 (−1.67--−0.52)   −5.53 (−6.43--−4.64)                      −8.30 (−9.40--−7.20)                                                                   
  Group difference                                                                    −0.32 (−1.13--0.49)    −0.15 (−1.43--1.13)                       −0.73 (−2.29--0.84)     N/A[¶](#t003fn006){ref-type="table-fn"}                        
  ADAS-Cog 12                                         Placebo time trend (per week)   0.120 (0.109--0.132)   N/A[¶](#t003fn006){ref-type="table-fn"}                                                                                          
  Nilvadipine change in trend                         −0.002 (−0.019--0.014)                                                                                                                                                                  
  CDR-sb                                              Placebo time trend (per week)   0.043 (0.040--0.047)   N/A[¶](#t003fn006){ref-type="table-fn"}                                                                                          
  Nilvadipine change in trend                         0.0005 (−0.005--0.005)                                                                                                                                                                  

Δ Change from baseline.

\*From F test for Visit × Arm interaction term. All models were controlled for baseline measurement and included country as a random effect and unstructured correlation between time points.

^Ɨ^Scores on the ADAS-Cog 12 range from 0 to 80, with higher scores indicating greater cognitive impairment \[[@pmed.1002660.ref018]\].

^ǂ^Scores on the CDR-sb range from 0 to 18, with higher scores indicating worse functioning \[[@pmed.1002660.ref019]\].

^§^Scores on the DAD range from 0 to 100, with higher scores indicating less impairment \[[@pmed.1002660.ref020]\].

¶ After the nonsignificant outcome on the primary outcome ADAS-Cog 12, all other primary and secondary gated outcomes are not judged for significance, as defined by the preplanned analysis.

Abbreviations: ADAS-Cog 12, Alzheimer\'s Disease Assessment Scale Cognitive-12; CDR-sb, Clinical Dementia Rating Scale sum of boxes; DAD, Disability Assessment for Dementia.

Per-protocol analyses showed identical patterns to the primary analysis. The prespecified responder analysis showed no effects of nilvadipine on the proportion of patients maintaining cognition or function as measured by the ADAS-Cog 12: odds ratio 1.09 (95% CI, 0.65--1.84), the CDR-sb: odds ratio 1.74 (95% CI, 0.99--3.06), or the DAD: odds ratio 0.90 (95% CI, 0.54--1.51).

The predefined subgroup analyses were inspected to identify group differences ([S2 Table](#pmed.1002660.s006){ref-type="supplementary-material"}, [S3 Table](#pmed.1002660.s007){ref-type="supplementary-material"}, [S4 Table](#pmed.1002660.s008){ref-type="supplementary-material"}); we note that no hypothesis tests were performed for these exploratory analyses. Comparing those with mild to those with moderate Alzheimer disease, there was less decline in the mild group on nilvadipine compared to placebo. However, a greater decline was seen in the moderate group treated with nilvadipine. For gender, males showed less decline than females on nilvadipine compared to placebo. Furthermore, *APOE* ε4 allele carriers showed less decline than noncarriers on nilvadipine ([S2 Table](#pmed.1002660.s006){ref-type="supplementary-material"}, [S3 Table](#pmed.1002660.s007){ref-type="supplementary-material"}, [S4 Table](#pmed.1002660.s008){ref-type="supplementary-material"}).

Safety {#sec019}
------

Participants who received at least one dose of the study drug comprised the safety population (*n* = 509). Despite a higher total number of AEs or serious adverse events (SAEs) in the nilvadipine group ([Table 4](#pmed.1002660.t004){ref-type="table"}) the number of patients with at least one AE or SAE were substantially similar. The median change in systolic blood pressure from baseline to week 78 was −5 mmHg and the number of falls, complaints of dizziness, or syncope were very similar between groups ([Table 4](#pmed.1002660.t004){ref-type="table"}). The number of deaths was 10 (7participants died during the study duration and a further 3 during the longer-term follow-up of SAEs). No deaths were judged by the investigators to be related to treatment. Emergent clinically significant blood test results on nilvadipine and placebo from baseline to week 78 were too rare to draw conclusions but were not elevated in the nilvadipine group. Between-group differences were observed on aggregated significant and nonclinically significant abnormal blood markers; these reflected more elevated results on placebo at trial end for creatinine (9%--13%) and calcium (7%--11%), or fewer elevated results on nilvadipine for mean corpuscular volume (MCV) results (10%--7%) ([S5 Table](#pmed.1002660.s009){ref-type="supplementary-material"}). A comparison of the Medical Dictionary for Regulatory Activities (MedDRA)-coded AEs ([S6 Table](#pmed.1002660.s010){ref-type="supplementary-material"}) showed small differences (\<6%) between groups for the following events: fall (worse on placebo), cough, cellulitis, peripheral edema, insomnia, and hypotension.

10.1371/journal.pmed.1002660.t004

###### Safety end points.

![](pmed.1002660.t004){#pmed.1002660.t004g}

  --------------------------------------------------------------------------------------
  Characteristics                                           Nilvadipine\   Placebo\
                                                            (*N* = 252)    (*N* = 257)
  --------------------------------------------------------- -------------- -------------
  ****Adverse Events****                                                   

  Total logged                                              1,129          1,030

  Possibly, Probably, or Definitely related to IMP          223            178

  Patients                                                  206 (82%)      201 (78%)

  Patients with Possibly, Probably, or Definitely related   142 (56%)      145 (56%)

  Patients with Dizziness                                   30 (12%)       29 (11%)

  Patients with Fall                                        40 (16%)       38 (15%)

  Patients with Fracture                                    16 (6%)        9 (4%)

  Patients with Peripheral edema                            15 (6%)        3 (1%)

  Patients with Syncope                                     12 (5%)        10 (4%)

  ****Serious Adverse Events****                                           

  Total logged                                              146            101

  Possibly, Probably, or Definitely related to IMP          17             19

  Patients                                                  50 (20%)       42 (16%)

  Patients with Possibly, Probably, or Definitely related   7 (3%)         9 (4%)

  **Mortality**[^Ɨ^](#t004fn001){ref-type="table-fn"}       3 (1.2%)       4 (1.6%)
  --------------------------------------------------------------------------------------

^Ɨ^Three further individuals died at or after week 82 of the study (all in the placebo group).

Note that patients are counted if they had one or more events of the type listed.

Abbreviations: CDR, CDR-sb (Clinical Dementia Rating sum of boxes); DAD, Disability Assessment for Dementia; DBP, diastolic blood pressure; IMP, investigational medicinal product; mITT, modified intention-to-treat; SBP, systolic blood pressure; SMMSE, Standardised Mini-Mental State Examination.

Discussion {#sec020}
==========

To our knowledge, this is the first definitive intervention study of nilvadipine, a DHP calcium channel blocker with demonstrated Aβ-lowering properties in animal studies, for the treatment of Alzheimer disease. The results of this study indicated no benefit of nilvadipine as a treatment in a population spanning mild to moderate Alzheimer disease. There were no obvious methodological limitations that could have contributed to these negative findings for the primary and secondary outcomes in the overall treatment population. Recruitment was to target, the dropout and missing data rates were low. The rate of decline in the placebo group on the ADAS-Cog 12 was consistent with previous Phase III clinical trials involving mild to moderate Alzheimer disease participants. Treatment and placebo arms were well balanced, although there were more patients with abnormal glucose levels and with diabetes in the nilvadipine group at baseline. The higher frequency of diabetes in the nilvadipine group is unlikely to have had a bearing on the overall negative finding, as the effect of diabetes on cognitive decline in established Alzheimer disease is unclear \[[@pmed.1002660.ref022]\]. Furthermore, data from a sub-study confirm that there was no significant imbalance between the nilvadipine and the placebo groups in terms of antihypertensive use (J. Claassen & M.G.M. Olde Rikkert, personal communication, see [S4 Text](#pmed.1002660.s004){ref-type="supplementary-material"}).

The overall safety and AE profile for nilvadipine was favourable in this older population. There was no significant difference in the number of deaths, AEs, or SAEs that could be attributed to treatment. Blood pressure effects were modest, with only a median 5 mmHg drop in systolic blood pressure from baseline to week 78 in the nilvadipine treated group.

The findings from the predefined subgroup analyses suggest differential effects of nilvadipine in those at a milder disease stage, in *APOE* ε4 allele carriers, and in males. However, no significance tests were conducted on these subgroups, and these findings will require further investigation to determine if there are specific subgroups within the overall population that respond either positively or negatively to nilvadipine treatment. For instance, consistent with other anti-amyloid treatment trials suggesting that milder patients may respond better \[[@pmed.1002660.ref023]\], in these exploratory analyses, those with an SMMSE \>20 appeared to decline at a slower rate than those with an SMMSE \<20. However, greater decline on the ADAS-Cog 12 in moderate-stage patients on nilvadipine treatment should also be noted. Similarly, the gender and *APOE* ε4 allele carrier results warrant further exploration, although the number of patients participating in the *APOE* study (64%) was fewer than the overall treatment population. Further exploratory analyses, making use of the sub-study data, will look for correlation between biomarkers (in both blood and cerebrospinal fluid \[CSF\]), cerebral blood flow, and other brain imaging data to better understand whether specific mechanisms, e.g., via a blood pressure--lowering pathway or changes in Aβ or tau correlate with cognitive change.

The strengths of this investigator-driven clinical trial include the successful recruitment and retention of participants and the conduct of the study to a high standard. There are, however, a number of issues related to the study design that could be considered for future trials of this nature that are suggested by our main findings. Firstly, a single-dose strategy was used, and it is possible that an insufficient dose was given to effect a treatment response. The side effect profile for nilvadipine in this older, mild to moderate Alzheimer disease population was favourable and the effect on blood pressure quite modest, so it would probably have been safe to give a higher dose. While we predicted that any effect of nilvadipine on cognition would be via an anti-amyloid rather than a blood pressure--lowering pathway, it is possible that a lack of benefit in the overall population may have been contributed to by the modest blood pressure--lowering effect of nilvadipine in this study. Secondly, the lack of biomarker confirmation of the diagnosis of Alzheimer disease, which could mean that up to 20% of patients included in the trial may not have had significant amyloid pathology \[[@pmed.1002660.ref024]\], could be taken into account in the design of future trials of this nature. A third issue to consider is the timing of the intervention in the course of Alzheimer disease. Many anti-amyloid treatments have failed in populations with established mild to moderate Alzheimer disease, and it is a commonly held belief that it may be too late to treat established dementia with amyloid-lowering drugs when there is already associated significant neuronal damage \[[@pmed.1002660.ref025]\]. Similarly, if cerebral hypoperfusion triggers or accelerates the deposition of amyloid pathology, intervention with a drug that can improve cerebral blood flow should occur at the earliest possible stage if it is to be effective as a disease-modifying agent. The latter two limitations reflect the rapidly evolving evidence over recent years since this study was designed, highlighting the ability and necessity of more detailed phenotyping and a focus on earlier-stage intervention. Treatment at the prodromal stage of the Alzheimer disease process might therefore be a more successful point at which to intervene with nilvadipine.

Conclusions {#sec021}
===========

This study of Nilvadipine at a dose of 8 mg found no overall effect on slowing the rate of cognitive decline in a population spanning mild to moderate Alzheimer disease.
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Aβ40

:   Amyloid beta 40 amino acid peptide

Aβ42

:   Amyloid beta 42 amino acid peptide

ADAS-Cog 12

:   Alzheimer\'s Disease Assessment Scale Cognitive Subscale-12

AE

:   adverse event

APOE

:   Apolipoprotein E gene

CDR-sb

:   Clinical Dementia Rating Scale sum of boxes

CSF

:   cerebrospinal fluid

DAD

:   Disability Assessment for Dementia

DBP

:   diastolic blood pressure

DHP

:   dihydropyridine

ECG

:   electrocardiogram

ICH GCP

:   International Conference on Harmonisation Good Clinical Practice

IMP

:   investigational medicinal product

IQR

:   interquartile range

MCV

:   mean corpuscular volume

MedDRA

:   Medical Dictionary for Regulatory Activities

mITT

:   modified intention-to-treat

NINCDS-ADRDA

:   National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's disease Criteria

SAE

:   serious adverse event; SBP, systolic blood pressure

SMMSE

:   Standardised Mini-Mental State Examination

Syst-Eur

:   Systolic Hypertension in Europe

UCD CSTAR

:   University College Dublin Centre for Support and Training in Analysis and Research
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